Seeking Alpha
View as an RSS Feed

Aristides Capital  

View Aristides Capital's Comments BY TICKER:
Latest comments  |  Highest rated
  • Biolase: On Its Third CEO In 3 Quarters As The Current CEO Resigns And Exits The Board [View article]
    Is it allowed or not allowed under the Seeking Alpha comment policy to point out that your last tweet regarding $BIOL, which pointed out that it was breaking to new lows, was favorite 17 times, once by you, and also by 16 other accounts which nearly all appear to be bots, as their twitter-stream substantially consists of one of two identical sets of retweets?

    If you have invented followers on Twitter, do you also have invented followers on SeekingAlpha?
    May 22, 2015. 03:26 PM | Likes Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    they show up in Dow Jones newswire.
    May 22, 2015. 02:59 PM | Likes Like |Link to Comment
  • Bluebird Bio: Exit Strategy [View article]
    ding ding ding. you win the Internet for today. what a beautiful, spot on comment.

    this company is something like "fully valued" today for thal and SCD, but frankly, it is the best in its class, and I would rather own a fully valued best-in-class company than a discounted 2nd tier one. reason being that I doubt sickle cell and thal turn out to be the last diseases that BLUE can cure. there are several other monogenetic diseases with significant markets that a lentiviral vector can probably treat. I hate to utter the words, but this is truly a "platform company."
    May 22, 2015. 01:09 PM | 1 Like Like |Link to Comment
  • Biolase: On Its Third CEO In 3 Quarters As The Current CEO Resigns And Exits The Board [View article]
    Yes, it's a shame indeed. Apparently the Seeking Alpha comment policy does not allow one to mention factual, historical remarks about an author's past. I find it useful when assessing the validity of a story to consider such information, but it is not allowed here, so it looks like we'll just have to go on the facts on the page as they are.
    May 21, 2015. 02:19 PM | Likes Like |Link to Comment
  • Biolase: On Its Third CEO In 3 Quarters As The Current CEO Resigns And Exits The Board [View article]
    200,000+ shares available at JP Morgan at 6%. bring the shorts, please.
    May 21, 2015. 12:13 PM | Likes Like |Link to Comment
  • Biolase: On Its Third CEO In 3 Quarters As The Current CEO Resigns And Exits The Board [View article]
    I realize that you are excellent at self-promotion, Mr. Dallas Salazar, but at what point did you forget that you are a stock blogger, whereas Feinberg and Schuler and the other insiders here are actual professional, successful buy-side investors?

    Compare performance records. One of you sells a subscription service (somehow, in spite of your last three long ideas on SA with a three month performance available all being DOWN at least 20%). The other has made hundreds of millions of dollars investing capital.

    The idea of you telling these guys that their investment is a zero is just utterly laughable.

    As for my "blind following," if the choice is to follow very successful investors at a price below what they recently paid, or to follow you at a worse entry, I think we know which would be the successful strategy 8 times out of 10.
    May 21, 2015. 11:41 AM | 1 Like Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    (DOW JONES) DJ Officer/Dir PFAFFLE Registers 14,850 Of CORMEDIX INC >CRMD
    DJ Officer/Dir PFAFFLE Registers 14,850 Of CORMEDIX INC >CRMD


    SOURCE: Form 144

    ISSUER: CORMEDIX INC
    SYMBOL: CRMD


    FILER: PFAFFLE ANTONY
    TITLE: Officer and Director
    BROKER: MORGAN STANLEY SMITH BARNEY LLC
    RESTRICTED SHARES TO SELL: 14,850 DATE REGISTERED: 5/18/2015
    APPROXIMATE DATE OF SALE: 5/13/2015

    The Form 144 is filed with the Securities and Exchange Commission to
    reflect the intention of any holder of restricted stock to sell those
    shares. After the 144 is mailed to the S.E.C., the filer is permitted
    to sell the shares, or any fraction of them, within 90 days.

    Form 144 Data Source: The Washington Service
    (info@washingtonservic... or 301-913-5100)

    (END) Dow Jones Newswires
    May 20, 2015 16:10 ET (20:10 GMT)
    May 21, 2015. 09:03 AM | Likes Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    (DOW JONES) DJ Officer/Dir PFAFFLE Registers 30,000 Of CORMEDIX INC >CRMD
    DJ Officer/Dir PFAFFLE Registers 30,000 Of CORMEDIX INC >CRMD


    SOURCE: Form 144

    ISSUER: CORMEDIX INC
    SYMBOL: CRMD


    FILER: PFAFFLE ANTONY
    TITLE: Officer and Director
    BROKER: MORGAN STANLEY SMITH BARNEY LLC
    RESTRICTED SHARES TO SELL: 30,000 DATE REGISTERED: 5/18/2015
    APPROXIMATE DATE OF SALE: 6/19/2015

    The Form 144 is filed with the Securities and Exchange Commission to
    reflect the intention of any holder of restricted stock to sell those
    shares. After the 144 is mailed to the S.E.C., the filer is permitted
    to sell the shares, or any fraction of them, within 90 days.

    Form 144 Data Source: The Washington Service
    (info@washingtonservic... or 301-913-5100)

    (END) Dow Jones Newswires
    May 20, 2015 16:10 ET (20:10 GMT)
    May 21, 2015. 09:03 AM | Likes Like |Link to Comment
  • Biolase: On Its Third CEO In 3 Quarters As The Current CEO Resigns And Exits The Board [View article]
    1. "The only chance left for BIOL is a punitive, dilutive, equity fund raising round"

    this is beyond absurd. there is $24 million of cash on the balance sheet thanks to the equity raise at $2.37 which was essentially 100% insiders.

    2. your speculation regarding Nugent is equally ridiculous.

    When the Mrs. and I are at the grocery store, she frequently looks at the tabloid headlines and asks "how can they get away with making this stuff up?" I tell her it's hard to prove libel in the U.S., and that most people just don't bother responding to every stupid thing that is written about them.

    Congrats that you happened to catch a few guys giving up on the stock on Nugent's departure. Now you offer nothing new but an attempt to push to trigger stop loss selling among retail investors by scaring them, likely so that you can quickly cover your short and move on.
    May 21, 2015. 09:01 AM | Likes Like |Link to Comment
  • The Baron Rothschild Would Buy OvaScience [View article]
    I generally don't have the sense to go long on a company that is bleeding money but has a great story. Mostly I just buy a lot of boring stuff and watch it go up, and short a little obvious crud at unsustainable prices.
    May 20, 2015. 10:44 PM | Likes Like |Link to Comment
  • The Baron Rothschild Would Buy OvaScience [View article]
    that data is not horrible. we've covered the last little bit of our short.
    May 20, 2015. 03:16 PM | Likes Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    if European patent is invalid due to prior art, it doesn't take a rocket scientist to figure out that U.S. patent would likely not withstand challenge either.

    regardless, they could have 10.5 years market exclusivity in the U.S., but 10.5 years is a lot less than 20+, and it usually takes a few years to ramp a drug. so that makes the company much less valuable to a potential partner, and makes the large upfront expense of a p3 clinical trial a much harder sell.
    May 19, 2015. 04:00 PM | 1 Like Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    I was a practicing doc from 2001-2008; there was a need to prevent catheter-related infections then, and yet, this product never caught on. It is on the market today in Germany, and can't catch on.

    As far as "if" the company achieves p3 success, if their patents are invalidated on the basis of prior art, there won't even ever be a p3 trial, unless it is conducted the NIH, and then the product will cost pennies a vial and have 30% gross margins and multiple manufacturers.

    I think CRMD is absurdly overvalued even if its patents hold up, but its clearly a zero if they don't.
    May 19, 2015. 12:31 PM | 1 Like Like |Link to Comment
  • Biolase: Why Your Dentist Is Short This Stock [View article]
    "Lasers are dead. That's why BIOL is looking to shift into the much faster growing Imaging vertical."

    "Rumor on The Street is (actually this isn't a rumor as ...I've said way too much already)..."

    what? what? WUT?
    May 19, 2015. 09:00 AM | 1 Like Like |Link to Comment
  • CorMedix: High Probability Of Phase 3 Success? [View article]
    We believe the p3 will cost on the order of $30 million.

    One simple question for you: if much of great data is from 2001 to 2004, why do you suppose it is that this asset has been unable to find major financial backing in the 11 years since then?

    This company is just one more in a long line of recent story stocks over the last two years where someone has raised a little bit of capital touting some magic asset that has been around for a long time and has gained absolutely zero traction with capable large pharmaceutical companies. It is a great recipe for a short, again and again.
    May 19, 2015. 08:40 AM | 1 Like Like |Link to Comment
COMMENTS STATS
389 Comments
494 Likes